An About Face As Biogen Says It Will File Aducanumab In Alzheimer’s

Biogen surprised investors with news that it will file aducanumab with the FDA based on data from more patients treated at the highest dose than in the interim futility analysis that led to termination of two Phase III studies in March.

Biogen revived once-discontinued aducanumab and plans to file for US FDA approval. • Source: Shutterstock

Biogen’s unexpected decision to pursue US Food and Drug Administration approval for its previously discontinued amyloid-targeting biologic aducanumab in Alzheimer’s disease was met with skepticism given the surprising nature of the turnaround.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

23 Apr 2025

• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Sebela’s Tegoprazan Poised For GERD Market

23 Apr 2025

• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

Pipeline Watch: Eight Approvals And Three Phase III Readouts

23 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

22 Apr 2025

• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

23 Apr 2025

• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.